Expert claims reprisal for opposing virus drug Trump touted

WASHINGTON — The head of a government agency combating the coronavirus pandemic is alleging that he was ousted for opposing politically connected efforts to promote a malaria drug that President Donald Trump touted without proof as a remedy for COVID-19.

Rick Bright, former director of the Biomedical Advanced Research and Development Authority, said in a statement Wednesday that he was summarily removed from his job on Tuesday and reassigned to a lesser role. His lawyers, Debra Katz and Lisa Banks, called it “retaliation plain and simple.”

Controversy has swirled around the malaria drug hydroxychloroquine since Trump started promoting it from the podium in the White House briefing room.

BARDA, the agency that Bright formerly headed, is a unit of the Department of Health and Human Services (HHS) created to counter threats from bioterrorism and infectious diseases. It has recently been trying to jump-start work on a vaccine for the coronavirus.

“I am speaking out because to combat this deadly virus, science — not politics or cronyism — has to lead the way,” Bright, who has a doctoral degree in immunology, said in his statement, which was released by his lawyers.

“Specifically, and contrary to misguided directives, I limited the broad use of chloroquine and hydroxychloroquine, promoted by the administration as a panacea, but which clearly lack scientific merit,” Bright said.

“I also resisted efforts to fund potentially dangerous drugs promoted by those with political connections,” he added.

Asked about Bright at Wednesday’s briefing, Trump said he “never heard of him.”

“The guy says he was pushed out of a job,” Trump said. “Maybe he was. Maybe he wasn’t. … I don’t know who he is.”

This Monday, April 6, 2020 file photo shows an arrangement of hydroxychloroquine pills in Las Vegas. According to a study released on Tuesday, April 21, 2020, the malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in an analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers report. (AP Photo/John Locher)

Bright and his lawyers are requesting investigations by the HHS inspector general and by the Office of Special Counsel, an independent agency that has as part of its charge the protection of government whistleblowers.

“While I am prepared to look at all options and to think ‘outside the box’ for effective treatments, I rightly resisted efforts to provide an unproven drug on demand to the American public,” Bright wrote.

He also alluded to “clashes with HHS political leadership” over his efforts to “invest early in vaccines and supplies critical to saving American lives.” One of the major criticisms of the Trump administration’s pandemic response is that little was done in the month of February to stockpile needed equipment.

“Science, in service to the health and safety of the American people, must always trump politics,” Bright said.

In a statement Wednesday night, HHS confirmed that Bright is no longer at the BARDA agency, but did not address his allegations of political interference in scientific matters.

HHS said it was Bright who had requested an emergency use authorization for chloroquine and hydroxychloroquine. In his statement, Bright had said he insisted that the authorization be limited to a restricted group of patients, those hospitalized with confirmed COVID-19 under the supervision of a doctor.

Hydroxychloroquine was given to patients in the New York area, the nation’s most intense COVID-19 hot spot. It is usually administered in combination with the antibiotic azithromycin.

The HHS inspector general’s office had no response to Bright’s request for an investigation. But on Capitol Hill, leading Democrats seconded the call for an inquiry.

“President Trump is not a doctor, a scientist, or a medical professional,” said Rep. Rosa DeLauro, D-Conn., who chairs a House panel that oversees HHS finances. “The notion that he and his political appointees are making personnel decisions based on how effective the president thinks drugs like chloroquine and hydroxychloroquine will be … is completely unacceptable.”

Danielle Brian, executive director of the Project on Government Oversight, a nonpartisan watchdog group, said, “Punishing this whistleblower for doing his job sends us back to the dark ages.”

Trump has repeatedly touted the malaria drug during his regular coronavirus briefings, calling it a “game changer,” and suggesting its skeptics would be proved wrong. He has offered patient testimonials that the drug is a lifesaver.

But a recent study of 368 patients in U.S. veterans hospitals found no benefit from hydroxychloroquine — and more deaths. The study was an early look at the medication, which has prompted debate in the medical community, with many doctors leery of using it.

Bright’s allegations were first reported by The New York Times.

An official biography describes him as a flu and infectious-disease expert who joined the agency 10 years ago and was focused on vaccine development. He also held the title of HHS deputy assistant secretary for preparedness and response, reporting to Dr. Robert Kadlec. HHS said Bright is now assigned to the National Institutes of Health, working on new approaches to testing.